Atlas Capital Advisors’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $227K | Sell |
452
-15
| -3% | -$7.2K | 0.02% | 438 |
|
|
2026
Q1 | $230K | Buy |
467
+130
| +39% | +$70.6K | 0.03% | 388 |
|
|
2025
Q4 | $195K | Buy |
+337
| New | +$191K | 0.02% | 424 |
|
|
2025
Q2 | $282K | Sell |
695
-52
| -7% | -$21.7K | 0.03% | 343 |
|
|
2025
Q1 | $372K | Hold |
747
| – | – | 0.05% | 305 |
|
|
2024
Q4 | $389K | Hold |
747
| – | – | 0.05% | 291 |
|
|
2024
Q3 | $462K | Hold |
747
| – | – | 0.07% | 236 |
|
|
2024
Q2 | $413K | Sell |
747
-100
| -12% | -$57.3K | 0.05% | 259 |
|
|
2024
Q1 | $492K | Hold |
847
| – | – | 0.08% | 220 |
|
|
2023
Q4 | $450K | Sell |
847
-50
| -6% | -$24.2K | 0.07% | 239 |
|
|
2023
Q3 | $454K | Hold |
897
| – | – | 0.07% | 204 |
|
|
2023
Q2 | $468K | Buy |
897
+375
| +72% | +$202K | 0.07% | 210 |
|
|
2023
Q1 | $301K | Hold |
522
| – | – | 0.05% | 282 |
|
|
2022
Q4 | $287K | Buy |
522
+75
| +17% | +$39.7K | 0.05% | 268 |
|
|
2022
Q3 | $227K | Hold |
447
| – | – | 0.04% | 324 |
|
|
2022
Q2 | $243K | Hold |
447
| – | – | 0.04% | 340 |
|
|
2022
Q1 | $264K | Buy |
447
+70
| +19% | +$40.2K | 0.04% | 304 |
|
|
2021
Q4 | $252K | Hold |
377
| – | – | 0.04% | 325 |
|
|
2021
Q3 | $215K | Hold |
377
| – | – | 0.03% | 333 |
|
|
2021
Q2 | $190K | Buy |
377
+12
| +3% | +$5.66K | 0.03% | 364 |
|
|
2021
Q1 | $167K | Hold |
365
| – | – | 0.03% | 349 |
|
|
2020
Q4 | $170K | Buy |
+365
| New | +$171K | 0.04% | 322 |
|
|
2020
Q3 | – | Sell |
-365
| Closed | -$132K | – | 569 |
|
|
2020
Q2 | $132K | Hold |
365
| – | – | 0.03% | 362 |
|
|
2020
Q1 | $104K | Sell |
365
-160
| -30% | -$50.5K | 0.03% | 358 |
|
|
2019
Q4 | $171K | Hold |
525
| – | – | 0.04% | 333 |
|
|
2019
Q3 | $153K | Sell |
525
-200
| -28% | -$57.3K | 0.05% | 358 |
|
|
2019
Q2 | $213K | Sell |
725
-150
| -17% | -$41.3K | 0.07% | 283 |
|
|
2019
Q1 | $240K | Sell |
875
-48
| -5% | -$11.9K | 0.09% | 240 |
|
|
2018
Q4 | $207K | Buy |
923
+48
| +5% | +$11.3K | 0.08% | 252 |
|
|
2018
Q3 | $216K | Hold |
875
| – | – | 0.07% | 282 |
|
|
2018
Q2 | $185K | Buy |
875
+325
| +59% | +$69K | 0.07% | 279 |
|
|
2018
Q1 | $114K | Buy |
+550
| New | +$115K | 0.03% | 329 |
|
Other funds holding TMO
Atlas Capital Advisors's TMO Position: Q2 2026 in Review
Atlas Capital Advisors reduced its Thermo Fisher Scientific (TMO) stake by 3.2% in Q2 2026, selling an estimated $7.2K and leaving 452 shares worth $227K. The position accounts for 0.02% of the portfolio, ranked #438.
Atlas Capital Advisors first reported a position in TMO in Q1 2018 and has held it in 32 quarters since. The position peaked at $492K in Q1 2024. 2,624 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Atlas Capital Advisors held 452 shares of Thermo Fisher Scientific worth $227K as of Q2 2026.
- Atlas Capital Advisors sold 15 Thermo Fisher Scientific shares in Q2 2026, an estimated $7.2K.
- Thermo Fisher Scientific made up 0.02% of Atlas Capital Advisors's portfolio in Q2 2026, its #438 holding.
- Atlas Capital Advisors first reported a position in Thermo Fisher Scientific in Q1 2018 and has held it in 32 quarters since.
- Atlas Capital Advisors's Thermo Fisher Scientific position peaked at $492K in Q1 2024.
- 2,624 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Atlas Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.